Balyasny Asset Management
MLNT

Balyasny Asset Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Balyasny Asset Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,047
Closed -$162K – 2482
2017
Q4 		$162K Buy
+2,047
New +$151K ﹤0.01% 1936

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Balyasny Asset Management's MLNT Position: Q1 2018 in Review

Balyasny Asset Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2018, closing a stake of 2,047 shares — an estimated $162K sold.

Balyasny Asset Management first reported a position in MLNT in Q4 2017 and held it in 1 quarter. The position peaked at $162K in Q4 2017. 83 funds tracked by Wall St. Rank hold MLNT as of Q1 2018.

  • Balyasny Asset Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 2,047 Melinta Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $162K.
  • Balyasny Asset Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Balyasny Asset Management's Melinta Therapeutics, Inc. Common Stock position peaked at $162K in Q4 2017.
  • 83 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Balyasny Asset Management's 13F filing for Q1 2018, filed 15 May 2018.